DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Spinal Muscular Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Muscular Atrophy Market Insights
Spinal Muscular Atrophy Overview
Spinal muscular atrophy (SMA) is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. Spinal Muscular Atrophy is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of Spinal Muscular Atrophy is known as ‘5q SMA’ due to its genetic cause.
Some of the key facts of the Spinal Muscular Atrophy Market Report:
- The Spinal Muscular Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the National Organization for Rare Disorders (NORD), the prevalence of all types of SMA has been estimated to be 4-7.8 per 100,000 live births.
- According to the study conducted by Lally et al., Spinal Muscular Atrophy genotype prevalence at birth consistently ranges from 8.5 — 10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000
- Key Spinal Muscular Atrophy Companies: Scholar Rock, Roche, Cytokinetics, and others
- Key Spinal Muscular Atrophy Therapies: Apitegromab, GYM329, Reldesemtiv, and others
- The Spinal Muscular Atrophy epidemiology based on gender analyzed that Spinal Muscular Atrophy (SMA) occurs equally in men and women
Get a Free sample for the Spinal Muscular Atrophy Market Report-
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market
Key benefits of the Spinal Muscular Atrophy Market report:
- Spinal Muscular Atrophy market report covers a descriptive overview and comprehensive insight of the Spinal Muscular Atrophy Epidemiology and Spinal Muscular Atrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Spinal Muscular Atrophy market report provides insights on the current and emerging therapies.
- Spinal Muscular Atrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Spinal Muscular Atrophy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Spinal Muscular Atrophy market.
Download the report to understand which factors are driving Spinal Muscular Atrophy epidemiology trends @ Spinal Muscular Atrophy Epidemiological Insights
Spinal Muscular Atrophy Market
The dynamics of the Spinal Muscular Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Spinal Muscular Atrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Spinal Muscular Atrophy Epidemiology Segmentation:
The Spinal Muscular Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Spinal Muscular Atrophy
- Prevalent Cases of Spinal Muscular Atrophy by severity
- Gender-specific Prevalence of Spinal Muscular Atrophy
- Diagnosed Cases of Episodic and Chronic Spinal Muscular Atrophy
Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to get launched during the study period. The analysis covers Spinal Muscular Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Spinal Muscular Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Spinal Muscular Atrophy market share @ Spinal Muscular Atrophy market forecast
Spinal Muscular Atrophy Therapies and Key Companies
- Apitegromab: Scholar Rock
- GYM329: Roche
- Reldesemtiv: Cytokinetics
Spinal Muscular Atrophy Market Drivers
- Newborn Screening for Spinal Muscular Atrophy
- Promising Upcoming Launches and Approval
- Raising Awareness for Spinal Muscular Atrophy
Scope of the Spinal Muscular Atrophy Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Spinal Muscular Atrophy Companies: Scholar Rock, Roche, Cytokinetics, and others
- Key Spinal Muscular Atrophy Therapies: Apitegromab, GYM329, Reldesemtiv, and others
- Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
- Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Spinal Muscular Atrophy Unmet Needs, KOL’s views, Analyst’s views, Spinal Muscular Atrophy Market Access and Reimbursement
Spinal Muscular Atrophy Market Barriers
- High-treatment Cost
- Competition for Spinal Muscular Atrophy Emerging Therapies
Table of Contents
1. Spinal Muscular Atrophy Market Report Introduction
2. Executive Summary for Spinal Muscular Atrophy
3. SWOT analysis of Spinal Muscular Atrophy
4. Spinal Muscular Atrophy Patient Share (%) Overview at a Glance
5. Spinal Muscular Atrophy Market Overview at a Glance
6. Spinal Muscular Atrophy Disease Background and Overview
7. Spinal Muscular Atrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Spinal Muscular Atrophy
9. Spinal Muscular Atrophy Current Treatment and Medical Practices
10. Spinal Muscular Atrophy Unmet Needs
11. Spinal Muscular Atrophy Emerging Therapies
12. Spinal Muscular Atrophy Market Outlook
13. Country-Wise Spinal Muscular Atrophy Market Analysis (2019–2032)
14. Spinal Muscular Atrophy Market Access and Reimbursement of Therapies
15. Spinal Muscular Atrophy Market Drivers
16. Spinal Muscular Atrophy Market Barriers
17. Spinal Muscular Atrophy Appendix
18. Spinal Muscular Atrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Spinal Muscular Atrophy treatment, visit @ Spinal Muscular Atrophy Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/